Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: In vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 865-874

  Rosenblum, Michael G ^a   Shawver, Laura K ^c   Marks, John W ^a   Brink, Jody ^b   Cheung, Lawrence ^a   Langton Webster, Beatrice ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYER AG   (Germany)

^c SUGEN INC   (United States)

^d Megabios Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CHIMERIC ANTIBODY; GELONIN; GENE PRODUCT; IMMUNOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG UPTAKE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING, COMPETITIVE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR STEM CELL ASSAY;

EID: 0032904481     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Baselga, J., Seidman, A. D., Rosen, P. P., and Norton, L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology, 11 (3 Suppl. 2): 43-48, 1997.
2. Meden, H., and Kuhn, W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur. J. Obstet. Gynecol. Reprod. Biol., 71: 173-179, 1997.
3. Cirisano, F. D., and Karlan, B. Y. The role of the HER-2/neu oncogene in gynecologic cancers. J. Soc. Gynecol. Invest., 3: 99-105, 1996.
4. Seshadri, R., Matthews, C., Dobrovic, A., and Horsfall, D. J. The significance of oncogene amplification in primary breast cancer. Int. J. Cancer, 43: 270-272, 1989.
5. Klijn, J. G., Berns, E. M., Bontenbal, M., and Foekens, J. Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat. Rev., 19 (Suppl. B): 45-63, 1993.
6. Margolis, B. L., Lax, I., Kris, R., Dombalagian, M., Honegger, A. M., Howk, R., Givol, D., Ullrich, A., and Schlessinger, J. All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. J. Biol. Chem., 264: 10667-10671, 1989.
7. Chen, X., Levkowitz, G., Tzahar, E., Karunagaran, D., Lavi, S., Ben-Baruch, N., Leitner, O., Ratzkin, B. J., Bacus, S. S., and Yarden, Y. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J. Biol. Chem., 271: 7620-7629, 1996.
8. Karunagaran, D., Tzahar, E., Liu, N., Wen, D., and Yarden, Y. Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinases. J. Biol. Chem., 270: 9982-9990, 1995.
9. Williams, R., Sanghera, J., Wu, F., Carbonaro-Hall, D., Campbell, D. L., Warburton, D., Pelech, S., and Hall, F. Identification of a human epidermal growth factor receptor-associated protein kinase as a new member of the mitogen-activated protein kinase/extracellular signal-regulated protein kinase family. J. Biol. Chem., 268: 18213-18217, 1993.
10. Kuivinen, E., Hoffman, B. L., Hoffman, P. A., and Carlin, C. R. Structurally related class I and class II receptor protein tyrosine kinases are down-regulated by the same E3 protein coded for by human group C adenoviruses. J. Cell Biol., 120: 1271-1279, 1993.
11. Connelly, P. A., and Stern, D. F. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade. Proc. Nat. Acad. Sci. USA, 87: 6054-6057, 1990.
12. Marengo, S. R., Sikes, R. A., Anezinis, P., Chang, S. M., and Chung, L. W. Metastasis induced by overexpression of p185neu-T after orthotopic injection into a prostatic epithelial cell line (NbE). Mol. Carcinog., 19: 165-175, 1997.
13. Suen, T. C., and Hung, M. C. c-myc reverses neu-induced transformed morphology by transcriptional repression. Mol. Cell. Biol., 11: 354-362, 1991.
14. Kapitanovic, S., Radosevic, S., Kapitanovic, M., Andelinovic, S., Ferencic, Z., Tavassoli, M., Primorac, D., Sonicki, Z., Spaventi, S., Pavelic, K., and Spaventi, R. The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology, 112: 1103-1113, 1997.
15. Maguire, H. C., Jr., and Greene, M. I. The neu (c-erbB-2) oncogene. Semin. Oncol., 16: 148-155, 1989.
16. Press, M. F., Pike, M. C., Hung, G., Zhou, J. Y. Ma, Y., George, J., Dietz-Band, J., James, W., Slamon, D. J., Batsakis, J. G., and El-naggar, A. K. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res., 54: 5675-5682, 1994.
17. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E,. Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
18. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
19. Torregrosa, D., Bolufer, P., Lluch, A., Lopez, J. A., Barragan, E., Ruiz, A., Guillem, V., Munarriz, B., Garcia, and Conde, J. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin. Chim. Acta, 262: 99-119, 1997.
20. Battifora, H., Gaffey, M., Esteban, J., Mehta, P., Bailey, A., Faucett, C., and Niland, J. Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Mod. Pathol., 4: 466-474, 1991.
21. Baselga, J., and Mendelsohn, J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol. Ther., 64: 127-154, 1994.
22. Rodriguez, G. C., Boente, M. P., Berchuck, A., Whitaker, R. S., O'Briant, K. C., Xu, F., and Bast, R. C., Jr. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am. J. Obstet. Gynecol., 168: 228-232, 1993.
23. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., and Norton, L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
24. Niehans, G. A., Singleton, T. P., Dykoski, D., and Kiang, D. T. Stability of HER-2/neu expression over time and at multiple metastatic sites. J. Natl. Cancer Inst., 85: 1230-1235, 1993.
25. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J., Mischak, R. P., and Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4575-4580, 1991.
26. Liu, H. L., Parkes, D. L., Langton, B. C., Xuan, J. A., Longhi, M., Elliger, S. S., Chao, L. A., McGrogan, M. P., Brandis, J. W., and Shawver, L. K. Construction of a chimeric antibody with therapeutic potential for cancers which overexpress. Biochem. Biophys. Res. Commun., 211: 792-803, 1995.
27. Rosenblum, M. G., Kohr, W. A., Beattie, K. L., Beattie, W. G., Marks, W., Toman, P. D., and Cheung, L. Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum. J. Int. Cyt. Res., 15: 547-555, 1995.
28. Rosenblum, M. G., Murray, J. L., Cheung, L., Rifkin, R., Salmon, S., and Bartholomew, R. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol. Biother., 3: 6-13, 1991.
29. McGraw, K. J., Rosenblum, M. G., Cheung, L., and Scheinberg, D. A. Characterization of murine and humanized anti-CD33 gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunol. Immunother., 39: 367-374, 1994.
30. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
31. Bendel, A. E., Shao, Y., Davies, S. M., Warman, B., Yang, C. H., Waddick, K. G., Uckun, F. M., and Perentesis, J. P. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor. Leuk. Lymph., 25: 257-270, 1997.
32. Suzuki, S., Uno, S., Fukuda, Y., Aoki, Y., Masuko, T., and Hashimoto, Y. Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Br. J. Cancer, 72: 663-668, 1995.
33. Tagliabue, E., Centis, F., Campiglio, M., Mastroianni, A., Martignone, S., Pellegrini, R., Casalini, P., Lanzi, C., Menard, S., and Colnaghi, M. I. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/neu gene amplification. Int. J. Cancer, 47: 93393-93397, 1991.
34. Tecce, R., Digiesi, G., Savarese, A., Trizio, D., and Natali, P. G. Characterization of cytotoxic activity of saporin anti-gp185/HER-2 immunotoxins. Int. J. Cancer, 55: 122-127, 1993.
35. Rodriguez, G. C., Boente, M. P., Berchuck, A., Whitaker, R. S., O'Briant, K. C., Xu, F., and Bast, R. C., Jr. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am. J. Obstet. Gynecol., 168: 228-232, 1993.
36. Press, M. F., Cordon-Cardo, C., and Slamon, D. J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5: 953-962, 1990.
37. r 30,000 form of ricin A chain. Cancer Res., 51: 4219-4225, 1991.
38. Wawrzynczak, E. J., Cumber, A. J., Henry, R. V., May, J., Newell, D. R., Parnell, G. D., Worrell, N. R., and Forrester, J. A. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin. Cancer Res., 50: 7519-7526, 1990.
39. Blakey, D. C., Watson, G. J., Knowles, P. P., and Thorpe, P. E. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res., 47: 947-952, 1987.
40. Klapper, L. N., Vaisman, N., Hurwitz, E., Pinkas-Kramarski, R., Yarden, Y., and Sela, M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene, 14: 2099-2109, 1997.
41. Kita, Y., Tseng, J., Horan, T., Wen, J., Philo, J., Chang, D., Ratzkin, B., Pacifici, R., Brankow, D., Hu, S., Luo, Y., Wen, D., Arakawa, T., and Nicolson, M. ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies. Biochem. Biophys. Res. Commun., 226: 59-69, 1996.
42. Parren, P. W. Preparation of genetically engineered monoclonal antibodies for human immunotherapy. Hum. Antib. Hybrid., 3: 137-145, 1992.
43. Reimann, K. A., Lin, W., Bixler, S., Browning, B., Ehrenfels, B. N., Lucci, J., Miatkowski, K., Olson, D., Parish, T. H., Rosa, M. D., Oleson, F. B., Hsu, Y. M., Padlan, E. A., Letvin, N. L., and Burkly, L. C. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res. Hum. Retroviruses, 13: 933-943, 1997.
44. Rosenblum, M. G., Cheung, L., Murray, J. L., and Bartholomew, R. Antibody-mediated delivery of tumor necrosis factor (TNF-α): improvement of cytotoxicity and reduction of cellular resistance. Cancer Commun., 3: 21-27, 1991.
45. Rosenblum, M. G., Cheung, L., Mujoo, K., and Murray, J. L. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. Cancer Immunol. Immunother., 40: 322-328, 1995.
46. Rosenblum, M., Cheung, L., and Parakh, C. Retargeting human cytokines: directing TNF to HER2/neu expressing tumor cells. Proc. Am. Assoc. Cancer Res., 38: 488, 1997.
47. Becker, J. C., Pancook, J. D., Gillies, S. D., Mendelsohn, J., and Reisfeld, R. A. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc. Natl Acad. Sci. USA, 93: 2702-2707, 1996.
48. Gillies, S. D., Reilly, E. B., Lo, K. M., and Reisfeld, R. A. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA, 89: 1428-1432, 1992.